Earnings
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Teva says it has 10 additional biosimilars in development for launch from 2028 onwards, extending its portfolio beyond 2027 as it targets European growth and expands through partnerships.
Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?
With the separation from its parent company now behind it, Samsung Bioepis celebrated its highest-ever annual revenues and outlined its vision of further growth.
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
The disposal of the Asia-Pacific business outside China to BGH Capital allows Aspen to refocus on core growth drivers, including GLP-1 products and restoring profitability in sterile manufacturing.
European Commission approval positions Celltrion to streamline hospital workflows, with modelling suggesting millions in potential annual savings for healthcare systems.
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline.
Formycon continues preaching its confidence that it will meet the full-year guidance, despite facing a steep revenue void of €35.5m needed to meet the target.
Biocon’s biosimilar and generic businesses both delivered double-digit revenue increases, with non-US markets increasingly playing a more important role in the growth strategy.
Supply-chain bottlenecks, heavy wholesaler de-stocking, and tighter working-capital controls sent Gedeon Richter’s General Medicines sales down by 17% and slashed adjusted EBIT by nearly two-thirds in Q3.
Capital tightening and shifting US regulations slowed contract manufacturing orders in Q3, though Richter sees normalization ahead as new European clients come online.
Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?
Favorable regulatory winds in the US are leading Lupin down the biosimilar path, as it also hopes that the potential US generic-first policy will boost its wider off-patent drug portfolio. However, it is also facing several facility compliance setbacks.
Spun out of Mallinckrodt following its merger with Endo, Par Health begins operations as a major US producer of generics, sterile injectables and APIs, while Mallinckrodt’s remaining branded arm rebrands as Keenova Therapeutics.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call.